Medicrea Showcases UNiD™ ASI Technology at Eurospine 2017 with the European Launch of its Proprietary UNiD™ HUB Software
The Medicrea Group (Euronext Growth Paris: FR0004178572 - ALMED), pioneering the convergence of healthcare IT and next-generation, outcome-centered device design and manufacturing with UNiD™ ASI technology, announced today that the Company will have a strong clinical and commercial presence at the Eurospine 2017 meeting in Dublin, Ireland, from the 11th to the 13th of October, where UNiD™ LAB biomedical engineers will demonstrate the Company’s UNiD™ ASI technology in their booth (#F16) and host the European Launch of their proprietary UNiD™ HUB software.
Denys Sournac, President and Chief Executive Officer, stated: “At Eurospine 2017, we will demonstrate to the international community of spine surgeons in attendance how UNiD™ ASI technology fills the void created by traditional manufacturers by launching UNiD™ HUB, a software platform that fully integrates surgical planning through machine learning to generate personalized implants that are adapted to surgeon and patient. We will further expand our commercialization efforts with the U.S. launch shortly thereafter at NASS 2017, from the 25th to the 27th of October in Orlando, Florida.”
On Wednesday, October 11th, Medicrea will host an exclusive European UNiD™ HUB launch event at the Teeling Whiskey Distillery, where Dr. Evalina Burger, of University Colorado Hospital, and Thomas Mosnier, PhD, Chief Scientific Officer at Medicrea, will introduce the patented and exclusive surgical planning, analytics and data visualization capabilities of the UNiD™ HUB software and share how Medicrea enables surgeons and healthcare providers to use proprietary data science to drive improved outcomes and economic efficiencies in spine surgery.
Two podium presentations featuring the clinical results achieved with Medicrea’s patient-specific UNiD™ Rods, generated by the Company’s UNiD™ ASI systems-based technology for personalized spinal care, will be given on Friday, October 13th. The lecture details are given below:
Are Patient-Specific Rods Effective to Manage Adult Spinal
Authored by Dr. V. Fiere, Dr. H. D’Astorg, Dr. M. Szadkowski and Dr. E. Burger.
Plenary Hall - New Techniques and Imaging Session from 2:00 to 3:20pm
Radiographic Comparison of Patient-Specific (PS) and
Manually-Contoured Conventional (C) Rods in Adolescent Idiopathic
Scoliosis (AIS) Surgery.
Authored by Dr. P. Alijanipour, Dr. M.J. Heffernan, Dr. N.K. Baldwin and Dr. A. King
Plenary Hall - New Techniques, Medical Economics Session from 3:50 to 5:00pm
Meeting attendees are invited to learn more about Medicrea at Booth #F16. To meet with Medicrea at Eurospine 2017 or express your interest in attending the official European UNiD™ HUB Launch event on Wednesday, October 11th, please contact Stephanie Sallamand at firstname.lastname@example.org .
About Medicrea ( www.Medicrea.com )
Through the lens of predictive medicine, Medicrea leads the design, integrated manufacture, and distribution of 30+ FDA approved spinal implant technologies that have been utilized in over 150,000 spinal surgeries to date. By leveraging its proprietary software analysis tools with big data and machine learning technologies and supported by an expansive collection of clinical and scientific data, Medicrea is well-placed to streamline the efficiency of spinal care, reduce procedural complications and limit time spent in the operating room.
Operating in a $10 billion marketplace, Medicrea is a Small and Medium sized Enterprise (SME) with 175 employees worldwide, which includes 50 who are based in the U.S. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D-printed titanium patient-specific implants.
For further information, please visit: Medicrea.com .
Medicrea is listed on
EURONEXT Growth Paris
ISIN: FR 0004178572
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
DE-INCYTE21.10.2018 12:47 | pressemeddelelse
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma
SERVIER21.10.2018 11:12 | pressemeddelelse
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer
IL-GILEAD-SCIENCES21.10.2018 00:32 | pressemeddelelse
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting
CA-TRUE-RELIGION19.10.2018 19:39 | pressemeddelelse
Manchester United and True Religion Launch Denim Range
ARCH-INSURANCE19.10.2018 15:12 | pressemeddelelse
Arch Insurance Announces Strategic Leadership Changes
MA-TAKEDA-PHARMACEUTICAL19.10.2018 14:02 | pressemeddelelse
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum